No Data
No Data
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $21 From $20, Maintains Overweight Rating
Teva Pharmaceutical Industries (TEVA) has an average outperform rating and price target range of $14.50 to $22, according to analysts polled by Capital IQ. Price: 16.76, Change: +0.13, Percent Change:
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annu
Teva Announced Saturday, Switching To UZEDY At Four Weeks After The Last Dose Of Once-monthly Paliperidone Palmitate Provided The Most Comparable Pharmacokinetic Profile Based On The Relevant PK Modeling Data For Schizophrenia
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA),today announced the presentation of seven studies from its long-acting injectable (LAI) schizophreni
Teva Presents First Real-World Data From the IMPACT-TD Registry Study at Psych Congress Elevate 2024
4 Analysts Assess Teva Pharmaceutical Indus: What You Need To Know
In the latest quarter, 4 analysts provided ratings for Teva Pharmaceutical Indus (NYSE:TEVA), showcasing a mix of bullish and bearish perspectives.The following table encapsulates their recent ratings
Teva Pharmaceutical Gains FDA Approval for Daily Huntington's Disease Pill
Teva Pharmaceutical Industries (TEVA) said Wednesday it had received US Food and Drug Administration approval for Austedo XR as a one-pill-per-day treatment option for patients with tardive dyskinesia
No Data